Bifeprunox + Placebo + Quetiapine
Phase 3Terminated 2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jun 1, 2008 → Nov 1, 2009
NCT ID
NCT00704509About Bifeprunox + Placebo + Quetiapine
Bifeprunox + Placebo + Quetiapine is a phase 3 stage product being developed by Lundbeck for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00704509. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00704509 | Phase 3 | Terminated |
| NCT00658645 | Phase 3 | Terminated |
Competing Products
20 competing products in Schizophrenia